Share the post "Vivanza Biosciences announced Financial Results Q1 2024-25"
Highlights
- The presented financial data is Consolidated to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company’s sales declined by -73.57 % over the year, decrease in net sales/revenue by -44.86 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -78.57 %, Marginal increase in other income during this quarter, up by 110.34%.
- Profit over the Year and quarter: Challenges in sustaining profitability for Vivanza Biosciences Limited. Profit dropped by -46.15 % Year to Year, Vivanza Biosciences Limited’s profitability dropped by -164.25 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -41.67 % Year to Year. EPS decreased by -170 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 9.228 Cr | Rs. 4.423 Cr | Rs. 2.439 Cr | -44.86 % | -73.57 % |
| Expenses | Rs. 8.64 Cr | Rs. 4.56 Cr | Rs. 2.08 Cr | -54.39 % | -75.93 % |
| Operating Profit | Rs. 0.59 Cr | Rs. -0.14 Cr | Rs. 0.36 Cr | + 357.14 % | -38.98 % |
| OPM % | 6.39 % | -3.17 % | 14.76 % | + 17.93 % | + 8.37 % |
| Other Income | Rs. 0.014 Cr | Rs. -0.029 Cr | Rs. 0.003 Cr | + 110.34 % | -78.57 % |
| Interest | Rs. 0.11 Cr | Rs. 0.09 Cr | Rs. 0.09 Cr | + 0 % | -18.18 % |
| Depreciation | Rs. 0 Cr | Rs. 0.01 Cr | Rs. 0 Cr | 0 % | 0 % |
| Profit before tax | Rs. 0.49 Cr | Rs. -0.27 Cr | Rs. 0.27 Cr | + 200 % | -44.9 % |
| Tax % | 0 % | -55.64 % | 0 % | + 55.64 % | 0 % |
| Net Profit | Rs. 0.49 Cr | Rs. -0.41 Cr | Rs. 0.27 Cr | + 165.85 % | -44.9 % |
| EPS in Rs | Rs. 0.12 | Rs. -0.1 | Rs. 0.07 | + 170 % | -41.67 % |
Today, we’re looking at Vivanza Biosciences Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -73.57 %. However, it did see a marginal slip of -44.86 % from the previous quarter. Expenses decreased slightly by -54.39 % quarter-on-quarter, aligning with the annual decline of -75.93 %. Operating profit, while down -38.98 % compared to last year, faced a quarter-on-quarter increase of 357.14 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 8.37 %, but an expansion of 17.93 % sequentially. Other income rose by 110.34 % compared to the last quarter, despite an annual decline of -78.57 %. Interest expenses surged remarkably by 0 % from the previous quarter, yet the year-over-year decrease remains at a moderate -18.18 %. Profit before tax declined annually by -44.9 % but saw an increase from the preceding quarter by 200 %.
with a more notable quarter-on-quarter increase of 55.64 %. Net profit fell by -44.9 % year-on-year but experienced a 165.85 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -41.67 % but a quarterly rise of 170 %. In summary, Vivanza Biosciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 9.228 Cr | Rs. 4.423 Cr | Rs. 2.439 Cr | -44.86 % | -73.57 % |
| Expenses | Rs. 8.64 Cr | Rs. 4.56 Cr | Rs. 2.08 Cr | -54.39 % | -75.93 % |
| Operating Profit | Rs. 0.59 Cr | Rs. -0.14 Cr | Rs. 0.36 Cr | + 357.14 % | -38.98 % |
| Net Profit | Rs. 0.49 Cr | Rs. -0.41 Cr | Rs. 0.27 Cr | + 165.85 % | -44.9 % |
| EPS in Rs | Rs. 0.12 | Rs. -0.1 | Rs. 0.07 | + 170 % | -41.67 % |
In reviewing Vivanza Biosciences Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -73.57 % year-on-year, although there was a slight dip of -44.86 % from the previous quarter. Expenses decreased by -75.93 % compared to the previous year, with a decrease of -54.39 % quarter-on-quarter. Operating Profit dropped by -38.98 % annually, and saw a 357.14 % increase from the last quarter.
Net Profit showed yearly decrease of -44.9 %, and experienced a 165.85 % increase from the previous quarter. Earnings Per Share (EPS) fell by -41.67 % annually, however rose by 170 % compared to the last quarter. In essence, while Vivanza Biosciences Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
